Nektar Therapeutics (NKTR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.27B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nektar Therapeutics (NKTR) Stock Forecast
Analysts expect Nektar Therapeutics (NKTR) to earn -$8.08 per share in the fiscal year ending Dec 31, 2026, on revenue of $41.82M. Of 15 analysts, 11 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.20, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 73% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 6.7% |
| Buy | 10 | 66.7% |
| Hold | 4 | 26.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 27.7%.
- Fiscal year ending Dec 31, 2026
- -$8.08
- EPS consensus, revenue $41.82M
- Fiscal year ending Dec 31, 2027
- -$10.50
- EPS consensus, revenue $53.42M
- Next report
- Mar 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$8.08 | -$9.63 to -$6.89 | 15 | $41.82M | $40.00M to $45.00M | 15 |
| Dec 31, 2027 | -$10.50 | -$20.03 to -$4.10 | 15 | $53.42M | $8.10M to $290.78M | 15 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.53 | -$3.43 to -$1.79 | 17 | $9.40M | $7.45M to $12.60M | 17 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 4 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$9.01.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$8.08 | -$8.08 | -$8.09 | -$8.18 | -$9.01 | N/A |
| Fiscal year ending Dec 31, 2027 | -$10.50 | -$10.50 | -$10.25 | -$10.54 | -$10.85 | N/A |
Frequently Asked Questions About NKTR
What is the NKTR stock forecast?
Consensus analyst estimates put Nektar Therapeutics's EPS at -$8.08 for the fiscal year ending Dec 31, 2026, on revenue of $41.82M. The consensus rating from 15 analysts is Buy.
How do analysts rate NKTR stock?
Of 15 analysts covering Nektar Therapeutics, 1 rates it Strong Buy, 10 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NKTR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$8.08, with estimates from -$9.63 to -$6.89 from 15 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$10.50, with estimates from -$20.03 to -$4.10 from 15 analysts.
What revenue do analysts expect from Nektar Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $41.82M, with estimates from $40.00M to $45.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $53.42M, with estimates from $8.10M to $290.78M.
How many analysts cover NKTR?
15 analysts rate Nektar Therapeutics stock, and 15 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NKTR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors